AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
← catalyst calendarNCT06793371 · readout ≤ 42 d
Sponsored by Cytokinetics (industry) · CYTK — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
60estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-06 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
- Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) — also filed as ulacamten
- Drug: Placebo to match CK-4021586
Primary outcomes
what the primary-completion date above is the date OFIncidence of early drug discontinuation
measured 12 weeks
Incidence of LVEF < 40%
measured 12 weeks
Incidence of AEs
measured 12 weeks
Permalink · CYTK's whole pipeline · Catalyst calendar · Every registered study · What changed